USPTO Launches "Patents 4 Patients": A Cancer Immunotherapy Program
OVERVIEW The Cancer Immunotherapy Pilot Program (also known as “Patents 4 Patients”) provides accelerated review without requiring a petition fee…
Read more
Amgen v. Apotex – Biosimilar Applicants Must Provide 180-Day Notice Before Marketing Even if They Participate in the "Patent Dance"
On July 5, 2016, the Federal Circuit rendered its decision in Amgen Inc. v. Apotex Inc., further clarifying the provisions…
USPTO Adds New Pilot Initiative That Could Help Move Pending Cases Through More Quickly – Combines Features of Pre-Appeal Conference & After-Final 2.0 Program
On July 11, the USPTO unveiled its Post-Prosecution Pilot Program (“P3”), which is scheduled to remain in effect until January…